|
Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma |
journalArticle |
2015 |
Izzedine, H.; Derosa, L.; Le Teuff, G.; Albiges, L.; Escudier, B. |
|
A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type |
journalArticle |
2018 |
Beylot-Barry, M.; Mermin, D.; Maillard, A.; Bouabdallah, R.; Bonnet, N.; Duval-Modeste, A. B.; Mortier, L.; Ingen-Housz-Oro, S.; Ram-Wolff, C.; Barete, S.; Dalle, S.; Maubec, E.; Quereux, G.; Templier, I.; Bagot, M.; Grange, F.; Joly, P.; Vergier, B.; Vially, P. J.; Gros, A.; Pham-Ledard, A.; Frison, E.; Merlio, J. P. |
|
Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G group |
journalArticle |
2016 |
Foulon, S.; Brennan, B.; Gaspar, N.; Dirksen, U.; Jeys, L.; Cassoni, A.; Claude, L.; Seddon, B.; Marec-Berard, P.; Whelan, J.; Paulussen, M.; Streitbuerger, A.; Oberlin, O.; Juergens, H.; Grimer, R.; Le Deley, M. C. |
|
Quality-of-Life Assessment in French Patients With Metastatic Melanoma in Real Life |
journalArticle |
2020 |
M;Kandel, S;Dalle, A;Bardet, C;Allayous, L;Mortier, C;Dutriaux, B;Guillot, M;Leccia, S;Dalac, D;Legoupil, P;Saiag, H;Montaudie, JP;Arnault, F;B.Possenti, JJ;Grob, J;DeQuatrebarbes, M;Beylot-Barry, T;Lesimple, F;Aubin, E;Maubec, F;Granel-Brocard, PE;Stoebner, A;Dupuy, B;Dreno, S;Michiels, C;Lebbe, I;Borget |
|
Innovative medical devices and hospital decision making: a study comparing the views of hospital pharmacists and physicians |
journalArticle |
2015 |
Billaux, M.; Borget, I.; Prognon, P.; Pineau, J.; Martelli, N. |
|
Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door |
journalArticle |
2018 |
Verlingue, L.; Hollebecque, A.; Lacroix, L.; Postel-Vinay, S.; Varga, A.; El Dakdouki, Y.; Baldini, C.; Balheda, R.; Gazzah, A.; Michot, J. M.; Marabelle, A.; Mir, O.; Arnedos, M.; Rouleau, E.; Solary, E.; De Baere, T.; Angevin, E.; Armand, J. P.; Michiels, S.; André, F.; Deutsch, E.; Scoazec, J. Y.; Soria, J. C.; Massard, C. |
|
Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors |
journalArticle |
2017 |
Bahleda, R.; Le Deley, M. C.; Bernard, A.; Chaturvedi, S.; Hanley, M.; Poterie, A.; Gazzah, A.; Varga, A.; Touat, M.; Deutsch, E.; Massard, C.; Van De Velde, H.; Hollebecque, A.; Sallansonnet-Froment, M.; Ricard, D.; Taillia, H.; Angevin, E.; Ribrag, V.; Soria, J. C. |
|
Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours |
journalArticle |
2016 |
Gizzi, M.; Oberic, L.; Massard, C.; Poterie, A.; Gwenael, L. T.; Loriot, Y.; Albiges, L.; Baciarello, G.; Michels, J.; Bossi, A.; Blanchard, P.; Escudier, B.; Fizazi, K. |
|
How to Model Survival In Cost-Effectiveness Analysis? Differences Between Markov and Partitioned Survival Analysis Models |
journalArticle |
2015 |
Minacori, R.; Bonastre, J.; Lueza, B.; Marguet, S.; Levy, P. |
|
Antiangiogenic Tyrosine Kinase Inhibitors: Occurrence and Risk Factors of Hemoptysis in Refractory Thyroid Cancer |
journalArticle |
2016 |
Lamartina, L.; Ippolito, S.; Danis, M.; Bidault, F.; Borget, I.; Berdelou, A.; Al Ghuzlan, A.; Hartl, D.; Blanchard, P.; Terroir, M.; Deandreis, D.; Schlumberger, M.; Baudin, E.; Leboulleux, S. |
|
Is primary tumour resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomised trials |
journalArticle |
2015 |
Faron, M.; Pignon, J. P.; Malka, D.; Bourredjem, A.; Douillard, J. Y.; Adenis, A.; Elias, D.; Bouché, O.; Ducreux, M. |
|
Phase I–II trial designs: how early should efficacy guide the dose recommendation process? |
journalArticle |
2018 |
Paoletti, X; Postel-Vinay, S |
|
Erratum to: Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis |
journalArticle |
2016 |
Lueza, B.; Rotolo, F.; Bonastre, J.; Pignon, J. P.; Michiels, S. |
|
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial |
journalArticle |
2015 |
Salgado, R.; Denkert, C.; Campbell, C.; Savas, P.; Nuciforo, P.; Aura, C.; de Azambuja, E.; Eidtmann, H.; Ellis, C. E.; Baselga, J.; Piccart-Gebhart, M. J.; Michiels, S.; Bradbury, I.; Sotiriou, C.; Loi, S. |
|
Treating Metastatic Prostate Cancer With Local Therapies: Is It Still Wishful Thinking? |
journalArticle |
2018 |
Bibault, J. E.; Blanchard, P. |
|
MRI-guided brachytherapy in locally advanced cervical cancer: Small bowel [Formula: see text] and [Formula: see text] are not predictive of late morbidity |
journalArticle |
2016 |
Petit, C.; Dumas, I.; Chargari, C.; Martinetti, F.; Maroun, P.; Doyeux, K.; Tailleur, A.; Haie-Meder, C.; Mazeron, R. |
|
Daily Biopsy Diagnosis in Surgical Pathology: Concordance Between Light Microscopy and Whole-Slide Imaging in Real-Life Conditions |
journalArticle |
2018 |
Villa, I.; Mathieu, M. C.; Bosq, J.; Auperin, A.; Pomerol, J. F.; Lacroix-Triki, M.; Scoazec, J. Y.; Dartigues, P. |
|
Mining the coding and non-coding genome for cancer drivers |
journalArticle |
2015 |
Li, J.; Drubay, D.; Michiels, S.; Gautheret, D. |
|
Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experience |
journalArticle |
2016 |
Bluthgen, M. V.; Boutros, C.; Fayard, F.; Remon, J.; Planchard, D.; Besse, B. |
|
Revisiting vascular contraindications for transoral robotic surgery for oropharyngeal cancer |
journalArticle |
2018 |
Gorphe, P.; Auperin, A.; Honart, J. F.; Ton Van, J.; El Bedoui, S.; Bidault, F.; Temam, S.; Kolb, F.; Qassemyar, Q. |
|
[Network meta-analyses: Interest and limits in oncology] |
journalArticle |
2016 |
Ribassin-Majed, L.; Pignon, J. P.; Michiels, S.; Blanchard, P. |
|
Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas |
journalArticle |
2018 |
Delahousse, J.; Verlingue, L.; Broutin, S.; Legoupil, C.; Touat, M.; Doucet, L.; Ammari, S.; Lacroix, L.; Ducreux, M.; Scoazec, J. Y.; Malka, D.; Paci, A.; Hollebecque, A. |
|
In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies? |
journalArticle |
2017 |
Aspeslagh, S.; Matias, M.; Palomar, V.; Dercle, L.; Lanoy, E.; Soria, J. C.; Postel-Vinay, S. |
|
[Reirradiation for head and neck squamous cell carcinoma: Indications and results] |
journalArticle |
2019 |
Biau, J.; Moreau, J.; Blanchard, P.; Thariat, J.; Miroir, J.; Lapeyre, M. |
|
Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study) |
journalArticle |
2015 |
Raynaud, C.; Greillier, L.; Mazieres, J.; Monnet, I.; Mastroianni, B.; Robinet, G.; Fraboulet, G.; Dixmier, A.; Berard, H.; Lamy, R.; Letreut, J.; Lena, H.; Oliviero, G.; Botta, S.; Vergnenegre, A.; Borget, I.; Chouaid, C. |
|
Bevacizumab versus anti-epidermal growth factor receptor in first-line metastatic colorectal cancer. A meta-analysis: The last building block? |
journalArticle |
2016 |
Ducreux, M.; Pignon, J. P. |
|
[Economic analysis of multinational clinical trials in oncology] |
journalArticle |
2018 |
Lejeune, C.; Lueza, B.; Bonastre, J. |
|
Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study |
journalArticle |
2017 |
Atlan, P.; Bayar, M. A.; Lanoy, E.; Besse, B.; Planchard, D.; Ramon, J.; Raynard, B.; Antoun, S. |
|
Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care |
journalArticle |
2015 |
Schneider, D.; Bianchini, G.; Horgan, D.; Michiels, S.; Witjes, W.; Hills, R.; Plun-Favreau, J.; Brand, A.; Lawler, M. |
|
Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review |
journalArticle |
2015 |
Chouaïd, C.; Crequit, P.; Borget, I.; Vergnenegre, A. |
|
Lung Adenocarcinoma as Part of the Li-Fraumeni Syndrome Spectrum: Preliminary Data of the LIFSCREEN Randomized Clinical Trial |
journalArticle |
2017 |
Caron, O.; Frebourg, T.; Benusiglio, P. R.; Foulon, S.; Brugières, L. |
|
Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer |
journalArticle |
2019 |
Le Rhun, E.; Wallet, J.; Mailliez, A.; Le Deley, M. C.; Rodrigues, I.; Boulanger, T.; Lorgis, V.; Barriere, J.; Robin, Y. M.; Weller, M.; Bonneterre, J. |
|
[The role of the expansion cohort in phase I trials in oncology: guidelines of the phase I HUB] |
journalArticle |
2015 |
Ezzalfani, M.; Dugue, A.; Mollevi, C.; Pulido, M.; Bonnetain, F.; Filleron, T.; Gal, J.; Gauthier, M.; Le Deley, M. C.; Le Tourneau, C.; Medioni, J.; Nguyen, J. M.; Chabaud, S.; Teixeira, L.; Thivat, E.; You, B.; Kramar, A.; Paoletti, X. |
|
C-Reactive Protein Values After Colorectal Resection: Can We Discharge a Patient With a C-Reactive Protein Value >100? A Retrospective Cohort Study |
journalArticle |
2019 |
Benoit, O.; Faron, M.; Margot, N.; Creavin, B.; Debove, C.; Tiret, E.; Parc, Y.; Lefevre, J. H. |
|
Prognostic factors of successful on-purpose tumor biopsies in metastatic cancer patients included in the SHIVA prospective clinical trial |
journalArticle |
2017 |
Desportes, E.; Wagner, M.; Kamal, M.; Salomon, A. V.; Deniziaut, G.; Pierron, G.; Rouleau, E.; Jouffroy, T.; Le Tourneau, C.; Paoletti, X.; Servois, V. |
|
Difference in Restricted Mean Survival Time for Cost-Effectiveness Analysis Using Individual Patient Data Meta-Analysis: Evidence from a Case Study |
journalArticle |
2016 |
Lueza, B.; Mauguen, A.; Pignon, J. P.; Rivero-Arias, O.; Bonastre, J.; Group, Mar-Lc Collaborative |
|
Nail toxicities induced by systemic anticancer treatments |
journalArticle |
2015 |
Robert, C.; Sibaud, V.; Mateus, C.; Verschoore, M.; Charles, C.; Lanoy, E.; Baran, R. |
|
Clinical evidence of variable proton biological effectiveness in pediatric patients treated for ependymoma |
journalArticle |
2016 |
Peeler, C. R.; Mirkovic, D.; Titt, U.; Blanchard, P.; Gunther, J. R.; Mahajan, A.; Mohan, R.; Grosshans, D. R. |
|
REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours |
journalArticle |
2015 |
Levy, C.; Allouache, D.; Lacroix, J.; Dugue, A. E.; Supiot, S.; Campone, M.; Mahe, M.; Kichou, S.; Leheurteur, M.; Hanzen, C.; Dieras, V.; Kirova, Y.; Campana, F.; Le Rhun, E.; Gras, L.; Bachelot, T.; Sunyach, M. P.; Hrab, I.; Geffrelot, J.; Gunzer, K.; Constans, J. M.; Grellard, J. M.; Clarisse, B.; Paoletti, X. |
|
Toward a model-based patient selection strategy for proton therapy: External validation of photon-derived normal tissue complication probability models in a head and neck proton therapy cohort |
journalArticle |
2016 |
Blanchard, P.; Wong, A. J.; Gunn, G. B.; Garden, A. S.; Mohamed, A. S.; Rosenthal, D. I.; Crutison, J.; Wu, R.; Zhang, X.; Zhu, X. R.; Mohan, R.; Amin, M. V.; Fuller, C. D.; Frank, S. J. |